View in EDS

Current therapies in rheumatoid arthritis: A Latin American perspective.

Saved in:
Bibliographic Details
Title: Current therapies in rheumatoid arthritis: A Latin American perspective.
Alternate Title: Las terapias actuales en la artritis reumatoide: una perspectiva latinoamericana.
Authors: Burgos-Vargas, Rubén1 r.burgos.vargas@gmail.com, Catoggio, Luis Jose2,3, Galarza-Maldonado, Claudio4, Ostojich, Kasmir5, Cardiel, Mario H.6
Source: Reumatología Clínica. mar/abr2013, Vol. 9 Issue 2, p106-112. 7p.
Subjects: RHEUMATOID arthritis treatment, LATIN Americans, SYNOVIAL membranes, TENDONS, RHEUMATOLOGISTS, TUMOR necrosis factors, INTERLEUKIN-6 receptors, DISEASES
Abstract (English): Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting the synovium of joints, tendons, and some extra-articular sites. RA prevalence in Latin America ranges from 0.4 to 1.6%. Early treatment of RA translates into a substantial reduction in the cost to society. In light of this, early disease clinics are being established in some countries. Barriers to RA management, such as delay in referral to rheumatologists and limited access to therapy, have been identified. Evidence-based treatment guidelines have been adapted by countries according to their own situations. The need for keeping accurate records of biologics prescribed has been addressed by biologic registries, thereby contributing toward a better understanding of rheumatic diseases and their treatment. Current biologics include the tumor necrosis factor (TNF)-α inhibitors (etanercept, infliximab, and adalimumab), B-cell depletion agent (rituximab), interleukin-6 receptor blocker (tocilizumab), and T-cell co-stimulatory blocker (abatacept). Future therapies include kinase inhibitors (tofacitinib and fostamatinib), alternative TNF-α inhibitors (golimumab and certolizumab), and biosimilars. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): La artritis reumatoide (AR) es una enfermedad sistémica e inflamatoria que afecta la membrana sinovial de las articulaciones, los tendones y algunos sitios extra-articulares. La prevalencia de la AR en Latinoamérica se encuentra entre 0.4-1.6%. El tratamiento precoz de la enfermedad se traduce en una reducción del costo para la sociedad. En vista de esto, se han establecido clínicas de AR temprana en varios países de la región. Se han identificado barreras para el tratamiento de la AR como lo son el retraso en la referencia al reumatólogo y limitaciones en el acceso al tratamiento. Varios países han desarrollado y adaptado guías para el tratamiento basadas en la evidencia y en sus propias realidades. La necesidad de tener registros detallados de las prescripciones de biológicos ha sido abordada con registros de biológicos lo que llevará a un mejor entendimiento de las enfermedades reumáticas y su tratamiento. Los biológicos disponibles en la actualidad son los inhibidores del factor de necrosis tumoral (TNF)-α (etanercept, infliximab y adalimumab), un agente depletor de células B (rituximab), un bloqueador del receptor de interleucina-6 (tocilizumab) y un bloqueador de la co-estimulación de células T (abatacept). En el futuro se incluirán los inhibidores de cinasas (tofacitinib y fostamatinib) e inhibidores del TNF-α alternativos (golimumab y certolizumab) y biosimilares. [ABSTRACT FROM AUTHOR]
Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 96000036
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Current therapies in rheumatoid arthritis: A Latin American perspective.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Las terapias actuales en la artritis reumatoide: una perspectiva latinoamericana.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Burgos-Vargas%2C+Rubén%22">Burgos-Vargas, Rubén</searchLink><relatesTo>1</relatesTo><i> r.burgos.vargas@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Catoggio%2C+Luis+Jose%22">Catoggio, Luis Jose</searchLink><relatesTo>2,3</relatesTo><br /><searchLink fieldCode="AR" term="%22Galarza-Maldonado%2C+Claudio%22">Galarza-Maldonado, Claudio</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Ostojich%2C+Kasmir%22">Ostojich, Kasmir</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Cardiel%2C+Mario+H%2E%22">Cardiel, Mario H.</searchLink><relatesTo>6</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Reumatología+Clínica%22">Reumatología Clínica</searchLink>. mar/abr2013, Vol. 9 Issue 2, p106-112. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22RHEUMATOID+arthritis+treatment%22">RHEUMATOID arthritis treatment</searchLink><br /><searchLink fieldCode="DE" term="%22LATIN+Americans%22">LATIN Americans</searchLink><br /><searchLink fieldCode="DE" term="%22SYNOVIAL+membranes%22">SYNOVIAL membranes</searchLink><br /><searchLink fieldCode="DE" term="%22TENDONS%22">TENDONS</searchLink><br /><searchLink fieldCode="DE" term="%22RHEUMATOLOGISTS%22">RHEUMATOLOGISTS</searchLink><br /><searchLink fieldCode="DE" term="%22TUMOR+necrosis+factors%22">TUMOR necrosis factors</searchLink><br /><searchLink fieldCode="DE" term="%22INTERLEUKIN-6+receptors%22">INTERLEUKIN-6 receptors</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASES%22">DISEASES</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting the synovium of joints, tendons, and some extra-articular sites. RA prevalence in Latin America ranges from 0.4 to 1.6%. Early treatment of RA translates into a substantial reduction in the cost to society. In light of this, early disease clinics are being established in some countries. Barriers to RA management, such as delay in referral to rheumatologists and limited access to therapy, have been identified. Evidence-based treatment guidelines have been adapted by countries according to their own situations. The need for keeping accurate records of biologics prescribed has been addressed by biologic registries, thereby contributing toward a better understanding of rheumatic diseases and their treatment. Current biologics include the tumor necrosis factor (TNF)-α inhibitors (etanercept, infliximab, and adalimumab), B-cell depletion agent (rituximab), interleukin-6 receptor blocker (tocilizumab), and T-cell co-stimulatory blocker (abatacept). Future therapies include kinase inhibitors (tofacitinib and fostamatinib), alternative TNF-α inhibitors (golimumab and certolizumab), and biosimilars. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: La artritis reumatoide (AR) es una enfermedad sistémica e inflamatoria que afecta la membrana sinovial de las articulaciones, los tendones y algunos sitios extra-articulares. La prevalencia de la AR en Latinoamérica se encuentra entre 0.4-1.6%. El tratamiento precoz de la enfermedad se traduce en una reducción del costo para la sociedad. En vista de esto, se han establecido clínicas de AR temprana en varios países de la región. Se han identificado barreras para el tratamiento de la AR como lo son el retraso en la referencia al reumatólogo y limitaciones en el acceso al tratamiento. Varios países han desarrollado y adaptado guías para el tratamiento basadas en la evidencia y en sus propias realidades. La necesidad de tener registros detallados de las prescripciones de biológicos ha sido abordada con registros de biológicos lo que llevará a un mejor entendimiento de las enfermedades reumáticas y su tratamiento. Los biológicos disponibles en la actualidad son los inhibidores del factor de necrosis tumoral (TNF)-α (etanercept, infliximab y adalimumab), un agente depletor de células B (rituximab), un bloqueador del receptor de interleucina-6 (tocilizumab) y un bloqueador de la co-estimulación de células T (abatacept). En el futuro se incluirán los inhibidores de cinasas (tofacitinib y fostamatinib) e inhibidores del TNF-α alternativos (golimumab y certolizumab) y biosimilares. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=96000036
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.reuma.2012.09.001
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 106
    Subjects:
      – SubjectFull: RHEUMATOID arthritis treatment
        Type: general
      – SubjectFull: LATIN Americans
        Type: general
      – SubjectFull: SYNOVIAL membranes
        Type: general
      – SubjectFull: TENDONS
        Type: general
      – SubjectFull: RHEUMATOLOGISTS
        Type: general
      – SubjectFull: TUMOR necrosis factors
        Type: general
      – SubjectFull: INTERLEUKIN-6 receptors
        Type: general
      – SubjectFull: DISEASES
        Type: general
    Titles:
      – TitleFull: Current therapies in rheumatoid arthritis: A Latin American perspective.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burgos-Vargas, Rubén
      – PersonEntity:
          Name:
            NameFull: Catoggio, Luis Jose
      – PersonEntity:
          Name:
            NameFull: Galarza-Maldonado, Claudio
      – PersonEntity:
          Name:
            NameFull: Ostojich, Kasmir
      – PersonEntity:
          Name:
            NameFull: Cardiel, Mario H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: mar/abr2013
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-print
              Value: 1699258X
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Reumatología Clínica
              Type: main
ResultId 1